Project Description

Author: Abdur-rahman et al.


Diabetic Macular Edema (DME) and Age-Related Macular Degeneration (AMD) are two significant causes of vision impairment and central vision loss that impose an increasingly high burden on both patients and healthcare systems worldwide. The preferred treatment for DME and AMD patients is the use of anti-vascular endothelial growth factor (VEGF) agents. These agents play a crucial role in triggering angiogenesis, enhancing vascular permeability, disrupting the blood retinal barrier, and inducing inflammatory reactions.1 At present there are three approved VEGF-agents for treatment of AMD and DME: Ranibiziumab, Aflibercept and Brolucizumab. Extensive evidence has demonstrated that the use of Ranibizumab and Aflibercept has significantly improved the visual outcomes of patients with DME and AMD. However, the need for frequent treatment sessions poses challenges for patients, including missed or discontinued treatment, leading to suboptimal visual acuity results in real-world settings compared to clinical trials.2,3 Therefore, with focus in finding ways to minimize the treatment burden on patients and caregivers while still preserving visual acuity, Brolucizumab, an intravitreal anti-VEGF drug, was approved for the treatment of both AMD and DME. With a molecular weight of 26 kDa, Brolucizumab allows for higher molar dosing, with a longer duration of action, improved tissue penetrability and reduction in injection number/treatment burden for patients with AMD and DME when compared with other anti-VEGF agents.2 However, ongoing research is continuously updating data regarding the safety and efficacy of Brolucizumab in treating DME and AMD. The purpose of this current study is to provide valuable insights from real-world cases of patients with AMD and DME who have received Brolucizumab either as primary therapy or as a switch therapy.

Status: Ongoing

Full-text link: Not available